Dragon Pharma BPC 157 5 mg - Pentadecapeptide Research Vial

Dragon Pharma BPC 157 5 mg - Pentadecapeptide Research Vial

Dragon Pharma BPC 157 5 mg supplies the pentadecapeptide BPC-157 as a lyophilised 5 mg vial. It is a research peptide, not an approved medicine: the compound has no licensed product anywhere and no human dosing label, so all work with it is laboratory work. BPC 157 for sale from a GMP manufacturer with independent batch testing and a Certificate of Analysis on file.

• BPC-157 pentadecapeptide - 5 mg per lyophilised vial
• Research material for tissue-repair and gut-lining models
• Half-life 7.9 to 30 minutes in rat studies, not established in humans
• GMP-manufactured, HPLC-verified, COA on file per batch

How BPC 157 Works

BPC-157 is a synthetic pentadecapeptide derived from a fragment of gastric juice protein, and research models describe effects on angiogenesis, fibroblast activity and gut mucosal repair. It is studied for tendon and ligament healing, for gastric and intestinal injury, and for vascular repair, which groups it with TB 500 and the copper peptide GHK-Cu. The measured half-life of 7.9 to 30 minutes comes from rat studies using intravenous and intramuscular dosing, and no human value is established, so timing is taken from animal data.

Research Amounts and Handling

No human dose exists for BPC-157, so every figure is research practice. Vendor material describes 250 to 500 mcg per day, and community reporting describes 150 to 375 mcg twice daily, both as published or anecdotal practice rather than clinical findings. Reconstitute the 5 mg vial with bacteriostatic water: 2 ml gives 2.5 mg per ml, so a 250 mcg amount measures 0.1 ml, and 5 ml gives 1 mg per ml, so the same amount measures 0.25 ml. Keep the powder at 2-8 C away from light and the solution refrigerated, and follow the short use window on the vial.

Quality & Authenticity

Every batch is produced under GMP conditions and checked by independent HPLC, with the Certificate of Analysis held for the batch. Reported effects are mainly local: pain or redness at the injection site, with headache and mild malaise described in user reports, and there are no systematic human safety data. BPC-157 is named in the WADA prohibited list, so it cannot be used in any tested setting, and the same is true of the Zyvex BPC-157 and BPC 157 5 mg listings.

For laboratory research only. Consult a healthcare professional before use.

Consult a healthcare professional before any cycle. Doses are common community protocols.